Group Structure and Shareholders
Operational Group Structure
Lonza’s activities are organized into two segments:
The Pharma&Biotech segment covers Custom Development and Manufacturing offerings directed to pharmaceutical markets, as well as offerings from Lonza’s Bioscience Solutions business for the bioresearch market. It includes five business units: Mammalian Manufacturing, Chemical and Microbial Manufacturing, Clinical Development Licensing, Emerging Technologies and Bioscience Solutions. This all-encompassing segment offers pharmaceutical and biotech industries Lonza’s recognized development and manufacturing know-how and broad technology platform.
Lonza’s Operational Units are divided into four: Pharma&Biotech Operations and Research & Technology, along with Specialty Ingredients Operations and Research & Technology.
The Corporate Functions include Human Resources, Finance & Controlling, IT, Corporate Development, Engineering, Legal / IP, Logistics and Purchasing, Quality, Corporate Communications and Investor Relations and Environment, Health and Safety.
Global Business Service Organization
The Global Business Service Organization (GBSO) supports our market activities by implementing corporate guidelines and driving service excellence. The GBSO is helping to facilitate Lonza’s profitable growth by establishing standardized and harmonized solutions that enable the implementation of innovations at pace and scale. Key focus areas are on the critical business support functions.
Holding Company and Listed Companies
Lonza Group Ltd, with registered office in Basel (CH), is the ultimate parent company of the Lonza Group. Except for Lonza Group Ltd, no company belonging to the Lonza Group is listed. Please refer to the Shares and Participation Certificates section, for information on the listed shares, the stock exchanges on which Lonza Group Ltd is listed and the market capitalization.
Principal Subsidiaries and Joint Ventures
The principal subsidiaries and joint ventures of the Lonza Group are shown in Note 32: Principal Subsidiaries and Joint Ventures.
According to disclosure notifications filed with Lonza, the following shareholders held more than 3% of the Lonza share capital as of 31 December 2016.
|BlackRock, Inc., New York, NY (USA)||10.34|
|Massachusetts Mutual Life Insurance Company, Springfield, MA (USA)||4.51|
|Norges Bank (the Central Bank of Norway), Oslo (NOR)||3.78|
Lonza knows of no other shareholder(s) that owned more than 3% of its share capital as of 31 December 2016. To Lonza’s best knowledge, the above-mentioned shareholders are not linked by any shareholders’ agreement or similar arrangement with respect to their shareholdings in Lonza or the exercise of shareholders’ rights. For a full review of the individual disclosure notifications made during 2016, please refer to the SIX Swiss Exchange disclosure platform.
Lonza Group Ltd has not entered into any cross-shareholdings.